 The report reviews all clinical trials listed in clinicaltrials.government for new drugs targeting Alzheimer's disease AD, highlighting the recent approval of adjucanumab and lacanemab, and ongoing trials investigating promising new drugs based on pathophysiology-based disease-modifying therapies, with a focus on recruiting participants in earlier stages of the disease. The report emphasizes the importance of conducting fundamental research prior to brain damage caused by AD.